ClinicalTrials.gg
CompletedNCT00796289Updated Sep 9, 2015

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

A Phase 2 interventional study of GnRH iontophoretic transdermal Lutrepatch and GnRH iontophoretic transdermal Lutrepatch in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 35 sites in United States. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2015-09-09.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 38 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Infertility by Ferring Pharmaceuticals — none open to participants now, 2 under way, none of them phase 3. Infertility · Ferring Pharmaceuticals.

Enrollment
9th of 27
350 · median 220
Started
2009
with 2 others
Phase 2
6 of 39
none open now
Registered
3rd of 39
by date

Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 6 in phase 2, and was the 3rd registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 39 studies in Infertility by Ferring Pharmaceuticals is open now. The open studies under Infertility, anywhere →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 38 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies in Infertility by Ferring Pharmaceuticals as a file.
02

Study summary

The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.

03

Conditions studied

  • Infertility

Keywords

  • anovulatory/oligoovulatory infertility
04

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females between the ages of 18 and 38 years
  2. Desire to become pregnant
  3. Infertile due to ovulatory dysfunction as described below:

    • Unable to conceive for at least 1 year and
    • Anovulatory (defined as 4 or fewer menstrual cycles per year) or Oligo-ovulatory (defined as menstrual cycle frequency > 45 days)

Exclusion criteria

Exclusion Criteria:

  1. Requires donor oocytes or sperm
  2. Two or more failed (defined as no biochemical pregnancy achieved) gonadotropin fertility treatment cycles - if previous gonadotropin success, no more than two failed subsequent cycles
  3. Use of insulin-sensitizing drugs (e.g., Metformin) within 1 month prior to progesterone challenge
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    GnRH High Target Delivery

    10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days

    Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate

  • Experimental
    GnRH Medium Target Delivery

    10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days

    Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate

  • Experimental
    GnRH Low Target Delivery

    10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days

    Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate

  • Active comparator
    Clomiphene Citrate

    Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days

    Drug: clomiphene citrate · Drug: placebo GnRH patch

  • Placebo comparator
    Placebo

    Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days

    Drug: placebo clomiphene citrate · Drug: placebo GnRH patch

Interventions

  • 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml

    Also known as: Lutrepatch, Gonadotropin-releasing hormone (GnRH)

  • 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml

    Also known as: Gonadotropin-releasing hormone (GnRH), Lutrepatch

  • 10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml

    Also known as: Gonadotropin-releasing hormone (GnRH), Lutrepatch

  • Oral, 50 mg daily for 5 days

    Also known as: various tradenames

  • Drugplacebo clomiphene citrate

    oral, taken for 5 days

  • Drugplacebo GnRH patch

    Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.

06

What researchers measure

Primary outcomes

  1. Ovulation rate

    Time frame: 30 days

Secondary outcomes

  1. Pregnancy rate

    Time frame: 30 days

  2. Incidence of Ovarian Hyperstimulation Syndrome (OHSS)

    Time frame: 30 days

  3. Incidence of skin irritation

    Time frame: 30 days

07

Study locations

35 sites
  • Watching Over Mothers and Babies Foundation
    Tucson, Arizona 85712, United States
  • NEA Women's Clinic
    Jonesboro, Arkansas 72401, United States
  • San Diego Fertility Center
    San Diego, California 92130, United States
  • Compass Clinical Research
    San Ramon, California 94583, United States
  • North Coast Women's Care Medical Group
    Vista, California 92083, United States
  • Huntington Reproductive Center
    Westlake Village, California 91361, United States
  • Florida Fertility Institute
    Clearwater, Florida 33759, United States
  • All Women's Healthcare of Wesy Broward, Inc.
    Plantation, Florida 33324, United States
  • Atlanta Center for Reproductive Medicine
    Atlanta, Georgia 30328, United States
  • Georgia Reproductive Specialists
    Atlanta, Georgia 30342, United States
  • Women's Health Practice
    Champaign, Illinois 61820, United States
  • University of Kentucky
    Lexington, Kentucky 40536-0293, United States
  • A Woman's Center for Reproductive Medicine
    Baton Rouge, Louisiana 70815, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Shady Grove Fertility Center
    Rockville, Maryland 20850, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Hutzel Women's Health Specialists
    Detroit, Michigan 48201, United States
  • CAREM Canadian American Reproductive Medicine
    Hamtramck, Michigan 48212, United States
  • Women's Clinic of Lincoln, P.C.
    Lincoln, Nebraska 68510, United States
  • Fertility Center of Las Vegas
    Las Vegas, Nevada 89117, United States
  • The Medical Group of Northern Nevada
    Reno, Nevada 89502, United States
  • Women's Health Research Center LLC
    Lawrenceville, New Jersey 08648, United States
  • Albert Einstein College of Medicine
    Bronx, New York 10461, United States
  • Columbia University
    New York, New York 10032, United States
  • Lyndhurst Gynecologic Associates
    Winston-Salem, North Carolina 27103, United States
  • Institute for Reproductive Health
    Cincinnati, Ohio 45209, United States
  • Greater Cincinnati OB/GYN, Inc./Reproductive Medicine Research
    Cincinnati, Ohio 45267-0457, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Clinical Trials of America Inc
    Eugene, Oregon 97401, United States
  • Center for Health and Healing
    Portland, Oregon 97239, United States
  • Greenville Hospital System
    Greenville, South Carolina 29605, United States
  • Research Memphis Associates, LLC
    Memphis, Tennessee 38119, United States
  • Center for Assisted Reproduction
    Bedford, Texas 76022, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • Center of Reproductive Medicine
    Webster, Texas 77598, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 24, 2008
Start
Feb 2009
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Results delay requested
Dec 16, 2010
Last update
Sep 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00796289
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
Feb 2009
Primary completion
Dec 2009
Completion
Jan 2010
Last update
Sep 9, 2015

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gonadotropin-Releasing Hormone

Start the discussion